Molecular Express, Inc.
Compton, CA Doing business as Molecular Express Inc. Molecular Express, Inc.
- UEI
- R1JMHFESEKD5
- CAGE
- 337D8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2630 Homestead Pl, Compton, CA 90220, USA
- Website
- molecularexpress.com
- Founded
- 1996
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Vesivax TLR7 formula | National Institute of Allergy and Infectious Diseases | $2,999,352 | |
| Design and engineering of vesivax HIV immunogen formulations | National Institute of Allergy and Infectious Diseases | $1,999,866 | |
| Preclinical development of a me-1001, a synthetic lung surfactant - project summary/abstract surfactant deficiency in… | National Heart Lung and Blood Institute | $2,999,490 | |
| EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI… | National Institute of Allergy and Infectious Diseases | $599,925 | |
| Niclosamide formulations for the treatment of influenza infections - project summary the principal goal of this… | National Institute of Allergy and Infectious Diseases | $596,958 |
About Molecular Express, Inc.
Molecular Express, Inc. is a minority-owned, self-certified small disadvantaged business specializing in innovative drug formulations, therapeutics, and vaccine technologies primarily focused on infectious diseases and respiratory health solutions. Registered in SAM.gov since 2004, the company develops advanced liposomal platforms and pharmaceutical formulations for various medical applications, with a particular emphasis on creating synthetic drug delivery systems and vaccine technologies that address unmet medical needs.
Through federal contract awards, Molecular Express has consistently secured contracts with the National Institute of Allergy and Infectious Diseases (NIAID) to develop advanced medical technologies. Their contract work has primarily focused on HIV vaccine research, including engineering novel HIV GP41 ectodomain antigens, developing Vesivax liposomal platforms for antigen delivery, and designing HIV immunogen formulations. The contracts are predominantly Small Business Innovation Research (SBIR) Program Phase I and Phase II awards, with total small business set-asides ranging from $300,000 to nearly $3 million. These contracts involve developing innovative vaccine technologies, co-adjuvant formulations, and exploring different delivery methods for infectious disease treatments, consistently working to advance medical research through their specialized technological platforms.
The company's federal grant awards have been similarly focused on advanced medical research, with significant work in developing synthetic lung surfactants and innovative treatments for respiratory conditions. Grants from the National Heart, Lung, and Blood Institute (NHLBI) and NIAID have supported projects such as preclinical development of ME-1001, a fully synthetic lung surfactant for treating neonatal respiratory distress syndrome, and exploring niclosamide formulations for treating influenza infections. These grant-funded projects aim to create cost-effective medical solutions with potentially transformative impacts on global public health, particularly in addressing critical medical challenges in respiratory medicine and infectious disease treatment. The grants range from approximately $300,000 to $1 million and are primarily structured as Project Grants under specific research programs targeting cardiovascular diseases and infectious disease interventions.
SBA capabilities narrative
Research and development in molecular biology, vaccine research, delivery platform technologies.
Quick answers
What is Molecular Express, Inc.'s UEI?
Molecular Express, Inc.'s Unique Entity ID (UEI) in SAM.gov is R1JMHFESEKD5.
What is Molecular Express, Inc.'s CAGE code?
Molecular Express, Inc.'s CAGE code is 337D8.
What is Molecular Express, Inc.'s primary NAICS code?
Molecular Express, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Molecular Express, Inc. located?
Molecular Express, Inc.'s physical address in SAM.gov is 2630 Homestead Pl, Compton, CA 90220, USA.
Is Molecular Express, Inc. registered in SAM.gov?
Yes. Molecular Express, Inc.'s SAM.gov registration is active through November 6, 2026.
What is Molecular Express, Inc.'s most recent federal award?
Molecular Express, Inc.'s most recent federal contract award is Vesivax TLR7 formula (75N93024C00017), from National Institute of Allergy and Infectious Diseases, on September 1, 2024.
On GovTribe
See Molecular Express, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors